PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
24451252-10	2014	Furthermore, the EGF receptor inhibitor GW2974 significantly suppressed THP- and EGF-enhanced PMN phagocytosis and p38 and ERK1/2 phosphorylation in differentiated HL-60 cells.	GW2974	40-46	epidermal growth factor receptor	Homo sapiens	17-29
28586051-6	2017	GW2974, an EGFR inhibitor, suppressed the protein expression of EGFR, inhibited cell proliferation, increased LDH activity, induced apoptosis and promoted caspase-3/-8 activities and Bax/Bcl-2 protein expression, downregulated PI3K, p-Akt and p-mTOR protein expression in the transfected HCC cells overexpressing miRNA-133b.	GW2974	0-6	epidermal growth factor receptor	Homo sapiens	11-15
28586051-6	2017	GW2974, an EGFR inhibitor, suppressed the protein expression of EGFR, inhibited cell proliferation, increased LDH activity, induced apoptosis and promoted caspase-3/-8 activities and Bax/Bcl-2 protein expression, downregulated PI3K, p-Akt and p-mTOR protein expression in the transfected HCC cells overexpressing miRNA-133b.	GW2974	0-6	epidermal growth factor receptor	Homo sapiens	64-68
28586051-6	2017	GW2974, an EGFR inhibitor, suppressed the protein expression of EGFR, inhibited cell proliferation, increased LDH activity, induced apoptosis and promoted caspase-3/-8 activities and Bax/Bcl-2 protein expression, downregulated PI3K, p-Akt and p-mTOR protein expression in the transfected HCC cells overexpressing miRNA-133b.	GW2974	0-6	caspase 3	Homo sapiens	155-167
28586051-6	2017	GW2974, an EGFR inhibitor, suppressed the protein expression of EGFR, inhibited cell proliferation, increased LDH activity, induced apoptosis and promoted caspase-3/-8 activities and Bax/Bcl-2 protein expression, downregulated PI3K, p-Akt and p-mTOR protein expression in the transfected HCC cells overexpressing miRNA-133b.	GW2974	0-6	BCL2 associated X, apoptosis regulator	Homo sapiens	183-186
28586051-6	2017	GW2974, an EGFR inhibitor, suppressed the protein expression of EGFR, inhibited cell proliferation, increased LDH activity, induced apoptosis and promoted caspase-3/-8 activities and Bax/Bcl-2 protein expression, downregulated PI3K, p-Akt and p-mTOR protein expression in the transfected HCC cells overexpressing miRNA-133b.	GW2974	0-6	BCL2 apoptosis regulator	Homo sapiens	187-192
28586051-6	2017	GW2974, an EGFR inhibitor, suppressed the protein expression of EGFR, inhibited cell proliferation, increased LDH activity, induced apoptosis and promoted caspase-3/-8 activities and Bax/Bcl-2 protein expression, downregulated PI3K, p-Akt and p-mTOR protein expression in the transfected HCC cells overexpressing miRNA-133b.	GW2974	0-6	AKT serine/threonine kinase 1	Homo sapiens	235-238
28586051-6	2017	GW2974, an EGFR inhibitor, suppressed the protein expression of EGFR, inhibited cell proliferation, increased LDH activity, induced apoptosis and promoted caspase-3/-8 activities and Bax/Bcl-2 protein expression, downregulated PI3K, p-Akt and p-mTOR protein expression in the transfected HCC cells overexpressing miRNA-133b.	GW2974	0-6	mechanistic target of rapamycin kinase	Homo sapiens	245-249
28586051-6	2017	GW2974, an EGFR inhibitor, suppressed the protein expression of EGFR, inhibited cell proliferation, increased LDH activity, induced apoptosis and promoted caspase-3/-8 activities and Bax/Bcl-2 protein expression, downregulated PI3K, p-Akt and p-mTOR protein expression in the transfected HCC cells overexpressing miRNA-133b.	GW2974	0-6	microRNA 133b	Homo sapiens	313-323
30592329-12	2019	GW2974 (EGFR inhibitor) increased SLC34A2 knockdown-inhibited cell proliferation, migration/invasion, as well as enhanced SLC34A2 knockdown-increased the TMZ sensitivity of glioma cells.	GW2974	0-6	epidermal growth factor receptor	Homo sapiens	8-12
30592329-12	2019	GW2974 (EGFR inhibitor) increased SLC34A2 knockdown-inhibited cell proliferation, migration/invasion, as well as enhanced SLC34A2 knockdown-increased the TMZ sensitivity of glioma cells.	GW2974	0-6	solute carrier family 34 member 2	Homo sapiens	34-41
24451252-10	2014	Furthermore, the EGF receptor inhibitor GW2974 significantly suppressed THP- and EGF-enhanced PMN phagocytosis and p38 and ERK1/2 phosphorylation in differentiated HL-60 cells.	GW2974	40-46	epidermal growth factor	Homo sapiens	17-20
24451252-10	2014	Furthermore, the EGF receptor inhibitor GW2974 significantly suppressed THP- and EGF-enhanced PMN phagocytosis and p38 and ERK1/2 phosphorylation in differentiated HL-60 cells.	GW2974	40-46	mitogen-activated protein kinase 1	Homo sapiens	115-118
24451252-10	2014	Furthermore, the EGF receptor inhibitor GW2974 significantly suppressed THP- and EGF-enhanced PMN phagocytosis and p38 and ERK1/2 phosphorylation in differentiated HL-60 cells.	GW2974	40-46	mitogen-activated protein kinase 3	Homo sapiens	123-129
22414725-0	2012	GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance.	GW2974	13-19	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	62-67
23115024-0	2013	Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.	GW2974	43-49	epidermal growth factor receptor	Homo sapiens	58-90
23115024-0	2013	Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.	GW2974	43-49	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
23115024-2	2013	In the present study, a dual EGFR and HER2 inhibitor (GW2974) was evaluated for its effects in GBM in vitro and in vivo.	GW2974	54-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
23115024-5	2013	By protein microarray and Western blot analyses, the p38 mitogen-activated protein kinase (MAPK) pathway was found to be activated in GBM cells under high-concentration GW2974.	GW2974	169-175	mitogen-activated protein kinase 14	Homo sapiens	53-89
22414725-8	2012	In addition, a docking model predicted the binding conformation of GW583340 and GW2974 to be within the transmembrane region of homology modeled human ABCB1 and ABCG2.	GW2974	80-86	ATP binding cassette subfamily B member 1	Homo sapiens	151-156
22414725-0	2012	GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance.	GW2974	13-19	ATP binding cassette subfamily B member 1	Homo sapiens	73-78
22414725-8	2012	In addition, a docking model predicted the binding conformation of GW583340 and GW2974 to be within the transmembrane region of homology modeled human ABCB1 and ABCG2.	GW2974	80-86	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	161-166
22414725-9	2012	We conclude that GW583340 and GW2974, at clinically achievable plasma concentrations, reverse ABCB1- and ABCG2-mediated MDR by blocking the drug efflux function of these transporters.	GW2974	30-36	ATP binding cassette subfamily B member 1	Homo sapiens	94-99
22414725-9	2012	We conclude that GW583340 and GW2974, at clinically achievable plasma concentrations, reverse ABCB1- and ABCG2-mediated MDR by blocking the drug efflux function of these transporters.	GW2974	30-36	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	105-110
22414725-3	2012	In the present study, we conducted in vitro experiments to evaluate if GW583340 and GW2974, structural analogues of lapatinib, could reverse ABCB1- and ABCG2-mediated MDR.	GW2974	84-90	ATP binding cassette subfamily B member 1	Homo sapiens	141-146
22414725-3	2012	In the present study, we conducted in vitro experiments to evaluate if GW583340 and GW2974, structural analogues of lapatinib, could reverse ABCB1- and ABCG2-mediated MDR.	GW2974	84-90	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	152-157
22414725-4	2012	Our results showed that GW583340 and GW2974 significantly sensitized ABCB1 and ABCG2 overexpressing MDR cells to their anticancer substrates.	GW2974	37-43	ATP binding cassette subfamily B member 1	Homo sapiens	69-74
22414725-4	2012	Our results showed that GW583340 and GW2974 significantly sensitized ABCB1 and ABCG2 overexpressing MDR cells to their anticancer substrates.	GW2974	37-43	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	79-84
22414725-5	2012	GW583340 and GW2974 significantly increased the intracellular accumulation of [(3)H]-paclitaxel in ABCB1 overexpressing cells and [(3)H]-mitoxantrone in ABCG2 overexpressing cells respectively.	GW2974	13-19	ATP binding cassette subfamily B member 1	Homo sapiens	99-104
22414725-6	2012	In addition, GW583340 and GW2974 significantly inhibited ABCG2-mediated transport of methotrexate in ABCG2 overexpressing membrane vesicles.	GW2974	26-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	57-62
22414725-6	2012	In addition, GW583340 and GW2974 significantly inhibited ABCG2-mediated transport of methotrexate in ABCG2 overexpressing membrane vesicles.	GW2974	26-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	101-106
17556544-2	2007	Here, we show that GW2974 (HER2/EGF receptor tyrosine kinase inhibitor), but not trastuzumab, activates AMP-activated protein kinase (AMPK), initiating a metabolic stress response in human cardiomyocytes that protects against TNFalpha-induced cell death.	GW2974	19-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
20962673-6	2010	On the basis of the MTT assay results, GW2974, a dual inhibitor of epidermal growth factor receptor and HER-2/neu, exhibited only a weak cytotoxic response in SS-ES-1 cells.	GW2974	39-45	epidermal growth factor receptor	Homo sapiens	67-99
20962673-6	2010	On the basis of the MTT assay results, GW2974, a dual inhibitor of epidermal growth factor receptor and HER-2/neu, exhibited only a weak cytotoxic response in SS-ES-1 cells.	GW2974	39-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-113
21673090-4	2011	Here, we show that expression of a 95-kDa tyrosine phosphorylated form of ErbB2, herein referred to as p95L (lapatinib-induced p95) was increased in ErbB2(+) breast cancer cells treated with potent ErbB2 TKIs (lapatinib, GW2974).	GW2974	221-227	erb-b2 receptor tyrosine kinase 2	Homo sapiens	74-79
21673090-4	2011	Here, we show that expression of a 95-kDa tyrosine phosphorylated form of ErbB2, herein referred to as p95L (lapatinib-induced p95) was increased in ErbB2(+) breast cancer cells treated with potent ErbB2 TKIs (lapatinib, GW2974).	GW2974	221-227	nibrin	Homo sapiens	103-106
21673090-4	2011	Here, we show that expression of a 95-kDa tyrosine phosphorylated form of ErbB2, herein referred to as p95L (lapatinib-induced p95) was increased in ErbB2(+) breast cancer cells treated with potent ErbB2 TKIs (lapatinib, GW2974).	GW2974	221-227	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-154
21673090-4	2011	Here, we show that expression of a 95-kDa tyrosine phosphorylated form of ErbB2, herein referred to as p95L (lapatinib-induced p95) was increased in ErbB2(+) breast cancer cells treated with potent ErbB2 TKIs (lapatinib, GW2974).	GW2974	221-227	erb-b2 receptor tyrosine kinase 2	Homo sapiens	149-154
20682802-5	2010	GW2974 effectively inhibited skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in wild-type and BK5.erbB2 mice, although a more marked effect was seen in BK5.erbB2 mice.	GW2974	0-6	erb-b2 receptor tyrosine kinase 2	Mus musculus	111-116
20682802-5	2010	GW2974 effectively inhibited skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in wild-type and BK5.erbB2 mice, although a more marked effect was seen in BK5.erbB2 mice.	GW2974	0-6	erb-b2 receptor tyrosine kinase 2	Mus musculus	169-174
20682802-7	2010	GW2974 inhibited 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperproliferation, which correlated with reduced activation of both the EGFR and erbB2.	GW2974	0-6	epidermal growth factor receptor	Mus musculus	145-149
20682802-7	2010	GW2974 inhibited 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperproliferation, which correlated with reduced activation of both the EGFR and erbB2.	GW2974	0-6	erb-b2 receptor tyrosine kinase 2	Mus musculus	154-159
20682802-9	2010	Furthermore, the marked sensitivity of BK5.erbB2 mice to the inhibitory effects of GW2974 during tumor promotion suggest greater efficacy for this compound when erbB2 is overexpressed or amplified as an early event in the carcinogenic process.	GW2974	83-89	erb-b2 receptor tyrosine kinase 2	Mus musculus	43-48
20682802-9	2010	Furthermore, the marked sensitivity of BK5.erbB2 mice to the inhibitory effects of GW2974 during tumor promotion suggest greater efficacy for this compound when erbB2 is overexpressed or amplified as an early event in the carcinogenic process.	GW2974	83-89	erb-b2 receptor tyrosine kinase 2	Mus musculus	161-166
19352663-8	2009	Additionally, animals exercised prior to DOX/GW2974 injections had significantly lower levels of myocardial lipid peroxidation and caspase-3 and -8 activities compared to their sedentary counterparts.	GW2974	45-51	caspase 3	Rattus norvegicus	131-147
17936675-3	2008	The goal of this study was to evaluate the chemopreventive effects of a dual inhibitor of EGFR and ErbB2 tyrosine kinases, GW2974, in the 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster cheek pouch model.	GW2974	123-129	epidermal growth factor receptor	Homo sapiens	90-94
17936675-3	2008	The goal of this study was to evaluate the chemopreventive effects of a dual inhibitor of EGFR and ErbB2 tyrosine kinases, GW2974, in the 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster cheek pouch model.	GW2974	123-129	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-104
17936675-8	2008	In summary, our study indicated that dual inhibition of EGFR and ErbB2 tyrosine kinases by GW2974 was effective in preventing oral carcinogenesis in DMBA-induced hamster cheek pouch model.	GW2974	91-97	epidermal growth factor receptor	Homo sapiens	56-60
17936675-8	2008	In summary, our study indicated that dual inhibition of EGFR and ErbB2 tyrosine kinases by GW2974 was effective in preventing oral carcinogenesis in DMBA-induced hamster cheek pouch model.	GW2974	91-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	65-70
18594201-7	2008	Our results show that treatments directed to ErbB1/2 receptors using GW-2974 (a generic ErbB1/2 inhibitor) activated AMPK, a key regulator in mitochondrial energy production pathways in human cardiac cells and cancer cells.	GW2974	69-76	epidermal growth factor receptor	Homo sapiens	45-52
18594201-7	2008	Our results show that treatments directed to ErbB1/2 receptors using GW-2974 (a generic ErbB1/2 inhibitor) activated AMPK, a key regulator in mitochondrial energy production pathways in human cardiac cells and cancer cells.	GW2974	69-76	epidermal growth factor receptor	Homo sapiens	88-95
18594201-9	2008	When treated in combination with TNFalpha, a known cytokine associated with cardiac toxicity, GW-2974 protected cardiac cells from cell death whereas Herceptin contributed to TNFalpha-induced cellular killing.	GW2974	94-101	tumor necrosis factor	Homo sapiens	33-41
18171992-9	2007	Activation of the epidermal growth factor receptor (EGFR) seemed to underlie the ability of TPA to activate Akt as both PD153035, an inhibitor of EGFR, and GW2974, a dual-specific inhibitor of both EGFR and erbB2, were able to effectively reduce TPA-induced Akt phosphorylation as well as TPA-stimulated EGFR and erbB2 tyrosine phosphorylation in a dose-dependent manner.	GW2974	156-162	epidermal growth factor receptor	Mus musculus	18-50
18171992-9	2007	Activation of the epidermal growth factor receptor (EGFR) seemed to underlie the ability of TPA to activate Akt as both PD153035, an inhibitor of EGFR, and GW2974, a dual-specific inhibitor of both EGFR and erbB2, were able to effectively reduce TPA-induced Akt phosphorylation as well as TPA-stimulated EGFR and erbB2 tyrosine phosphorylation in a dose-dependent manner.	GW2974	156-162	epidermal growth factor receptor	Mus musculus	52-56
17556544-2	2007	Here, we show that GW2974 (HER2/EGF receptor tyrosine kinase inhibitor), but not trastuzumab, activates AMP-activated protein kinase (AMPK), initiating a metabolic stress response in human cardiomyocytes that protects against TNFalpha-induced cell death.	GW2974	19-25	epidermal growth factor	Homo sapiens	32-35
17556544-2	2007	Here, we show that GW2974 (HER2/EGF receptor tyrosine kinase inhibitor), but not trastuzumab, activates AMP-activated protein kinase (AMPK), initiating a metabolic stress response in human cardiomyocytes that protects against TNFalpha-induced cell death.	GW2974	19-25	ret proto-oncogene	Homo sapiens	36-60
17556544-2	2007	Here, we show that GW2974 (HER2/EGF receptor tyrosine kinase inhibitor), but not trastuzumab, activates AMP-activated protein kinase (AMPK), initiating a metabolic stress response in human cardiomyocytes that protects against TNFalpha-induced cell death.	GW2974	19-25	tumor necrosis factor	Homo sapiens	226-234
16934227-4	2006	We have shown that the RTK inhibitor GW282974A (an analogue of GW2016; lapatinib) is effective in chemosensitisation of drug resistant EGFR over-expressing cells giving rise to a synergistic effect when used in combination with either cisplatin or paclitaxel in chemosensitivity assays.	GW2974	37-46	ret proto-oncogene	Homo sapiens	23-26
17203189-8	2007	EGFR/HER-2/neu tyrosine kinase inhibitors (lapatinib and GW2974) were combined with Bcl-2 inhibitors (HA14-1 or GX15-070) and the anti-proliferative effects were determined by the MTT tetrazolium dye assay.	GW2974	57-63	epidermal growth factor receptor	Homo sapiens	0-4
17203189-10	2007	A synergistic inhibitory effect was observed with the combination of inhibitors of EGFR-HER-2/neu (lapatinib or GW2974) and Bcl-2 (GX15-070 or HA14-1) on the growth of the MCF-7, MCF/18, and MTR-3 human breast cancer cell lines.	GW2974	112-118	epidermal growth factor receptor	Homo sapiens	83-87
17203189-10	2007	A synergistic inhibitory effect was observed with the combination of inhibitors of EGFR-HER-2/neu (lapatinib or GW2974) and Bcl-2 (GX15-070 or HA14-1) on the growth of the MCF-7, MCF/18, and MTR-3 human breast cancer cell lines.	GW2974	112-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-93
17203189-10	2007	A synergistic inhibitory effect was observed with the combination of inhibitors of EGFR-HER-2/neu (lapatinib or GW2974) and Bcl-2 (GX15-070 or HA14-1) on the growth of the MCF-7, MCF/18, and MTR-3 human breast cancer cell lines.	GW2974	112-118	erb-b2 receptor tyrosine kinase 2	Mus musculus	94-97
16934227-4	2006	We have shown that the RTK inhibitor GW282974A (an analogue of GW2016; lapatinib) is effective in chemosensitisation of drug resistant EGFR over-expressing cells giving rise to a synergistic effect when used in combination with either cisplatin or paclitaxel in chemosensitivity assays.	GW2974	37-46	epidermal growth factor receptor	Homo sapiens	135-139
16934227-6	2006	A reduction in the downstream signalling effector phosphorylated ERK was seen in both resistant cell lines when GW282974A was used in combination with either cisplatin or paclitaxel.	GW2974	112-121	EPH receptor B2	Homo sapiens	65-68
16934227-9	2006	However, the paclitaxel resistant cell line appeared more sensitive to the chemosensitising effects of GW282974A, in line with its increased EGFR expression.	GW2974	103-112	epidermal growth factor receptor	Homo sapiens	141-145
16061875-7	2005	In addition, we examined the effect of another quinazoline derivative, GW2974, which is able to block the activation of both the EGFR and erbB2, in this model.	GW2974	71-77	epidermal growth factor receptor	Mus musculus	129-133
16061875-7	2005	In addition, we examined the effect of another quinazoline derivative, GW2974, which is able to block the activation of both the EGFR and erbB2, in this model.	GW2974	71-77	erb-b2 receptor tyrosine kinase 2	Mus musculus	138-143